INS and helminthiasis: In a double-blind, household-cluster-randomized, placebo-controlled clinical trial of people with and without mixed helminth infections, no differences in levels of insulin or glucose or HOMA-IR were observed at baseline, but those with helminth infections who were randomized to receive albendazole treatment experienced a significant increase in insulin resistance (HOMA-IR) at 52 weeks compared to those randomized to placebo treatment (estimated treatment effect, 0.031 [95% CI, 0.004–0.059]; P = 0.04) [8].